Xenon to Report Q3 2025 Financial Results on November 3, 2025
Xenon Pharmaceuticals (Nasdaq: XENE) will report third quarter 2025 financial results and provide a business update after U.S. market close on Monday, November 3, 2025 at 4:30 PM ET (1:30 PM PT). A live webcast and replay will be available on Xenon’s investors website; dial-in details and conference ID are provided for callers.
The company is a neuroscience-focused biopharmaceutical developer; its lead molecule azetukalner is in Phase 3 trials for epilepsy, major depressive disorder and bipolar depression, and Xenon also has Phase 1 Kv7 and Nav1.7 pain programs.
Xenon Pharmaceuticals (Nasdaq: XENE) annuncerà i risultati finanziari del terzo trimestre 2025 e fornirà un aggiornamento sull'andamento aziendale dopo la chiusura dei mercati statunitensi lunedì 3 novembre 2025 alle 16:30 ET (13:30 PT). Una versione in streaming in diretta e la replica saranno disponibili sul sito investitori di Xenon; i dettagli della chiamata e l'ID conferenza sono forniti agli interlocutori.
L'azienda è uno sviluppatore biofarmaceutico focalizzato sulle neuroscienze; la sua molecola leader azetukalner è in studi di fase 3 per epilessia, disturbo depressivo maggiore e depressione bipolare, e Xenon ha anche programmi di dolore Kv7 e Nav1.7 in fase 1.
Xenon Pharmaceuticals (Nasdaq: XENE) informará sobre los resultados financieros del tercer trimestre 2025 y proporcionará una actualización comercial después del cierre del mercado de EE. UU. el lunes 3 de noviembre de 2025 a las 4:30 PM ET (1:30 PM PT). Una transmisión en vivo y una repetición estarán disponibles en el sitio web de inversores de Xenon; se proporcionarán los detalles de marcación y el ID de la conferencia para los llamantes.
La compañía es un desarrollador biofarmacéutico centrado en neurociencias; su molécula líder azetukalner está en ensayos de fase 3 para epilepsia, trastorno depresivo mayor y depresión bipolar, y Xenon también tiene programas de dolor Kv7 y Nav1.7 en fase 1.
Xenon Pharmaceuticals (나스닥: XENE)은 2025년 3분기 재무 실적 발표와 비즈니스 업데이트를 미국 시장 마감 후 2025년 11월 3일 월요일 오후 4:30 PM ET (태평양 표준시 1:30 PM)에 제공할 예정입니다. 라이브 웹캐스트 및 재방송은 Xenon의 투자자 웹사이트에서 이용 가능하며, 전화 연결 정보 및 컨퍼런스 ID가 전화자에게 제공됩니다.
회사는 신경과학에 중점을 둔 바이오의약품 개발사로, 선도 물질인 azetukalner는 간질, 주요 우울장애 및 양극성 우울증에 대해 3상 임상시험 중이며, Xenon은 또한 Kv7 및 Nav1.7 통증 프로그램을 1상으로 보유하고 있습니다.
Xenon Pharmaceuticals (Nasdaq : XENE) publiera les résultats financiers du troisième trimestre 2025 et fournira une mise à jour commerciale après la clôture du marché américain le lundi 3 novembre 2025 à 16h30 ET (13h30 PT). Une diffusion en direct et une relecture seront disponibles sur le site des investisseurs de Xenon; les détails d'appel et l'ID de conférence sont fournis aux interlocuteurs.
L'entreprise est un développeur biopharmaceutique axé sur les neurosciences; sa molécule leader azetukalner est en essais de phase 3 pour l'épilepsie, le trouble dépressif majeur et la dépression bipolaire, et Xenon dispose également de programmes de douleur Kv7 et Nav1.7 en phase 1.
Xenon Pharmaceuticals (Nasdaq: XENE) wird die Finanzergebnisse für das dritte Quartal 2025 melden und ein Geschäftsupdating nach Börsenschluss in den USA am Montag, dem 3. November 2025 um 16:30 ET (1:30 PT) geben. Ein Live-Webcast und eine Wiedergabe werden auf der Anleger-Website von Xenon verfügbar sein; Anrufnummern und die Konferenz-ID werden den Anrufern mitgeteilt.
Das Unternehmen ist ein auf Neurowissenschaften fokussierter Biopharma-Entwickler; sein führendes Molekül Azetukalner befindet sich in Phase 3 Studien für Epilepsie, schwere depressive Störung und bipolare Depression, und Xenon besitzt auch Phase-1-Programme für Schmerzen Kv7 und Nav1.7.
Xenon Pharmaceuticals (نيويورك: XENE) ستعلن عن النتائج المالية للربع الثالث من 2025 وتقديم تحديث عن الأعمال بعد إغلاق السوق الأمريكية يوم الاثنين 3 نوفمبر 2025 الساعة 4:30 مساءً بتوقيت شرق الولايات المتحدة (1:30 مساءً بتوقيت المحيط الهادئ). ستكون هناك بث مباشر وإعادة عرض متاحان على موقع Xenon للمستثمرين؛ سيتم تزويد المتصلين بتفاصيل الاتصال ومعرف المؤتمر.
الشركة مطور أدوية حيويّة تركّز على علم الأعصاب؛ جزيئها الرائد azetukalner في دراسات المرحلة 3 لعلاج الصرع، واضطراب depressed major والاكتئاب ثنائي القطب، ولدى Xenon أيضًا برامج ألم Kv7 و Nav1.7 في المرحلة 1.
Xenon Pharmaceuticals (Nasdaq: XENE) 将在美国市场收盘后于 2025 年 11 月 3 日，星期一美国东部时间下午 4:30（太平洋时间 1:30 PM）公布 2025 年第三季度财务业绩并提供业务更新。现场直播及重播将可在 Xenon 的投资者网站上观看；拨号信息和会议 ID 将提供给致电者。
该公司是一家聚焦神经科学的生物制药开发商；其领先分子 azetukalner 正处于癫痫、重性抑郁障碍和双相抑郁症的 III 期试验阶段，Xenon 还拥有 Kv7 和 Nav1.7 疼痛的 1 期项目。
- None.
- None.
VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, November 3, 2025.
Conference Call/Webcast Information:
| Date: | Monday, November 3, 2025 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Webcast: | Pre-register here |
| Dial-In: | (800) 715-9871 toll-free or (646) 307-1963 for international callers |
| Conference ID: | 3971394 |
A live webcast of the company presentation will be available on the Investors section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contact:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
Media: media@xenon-pharma.com
Investors: investors@xenon-pharma.com
FAQ
When will Xenon (XENE) report Q3 2025 results and provide a business update?
How can investors access Xenon (XENE) Q3 2025 webcast and replay?
What are the dial-in details for Xenon (XENE) November 3, 2025 conference call?
What clinical programs will Xenon (XENE) likely discuss in the Q3 2025 update?
Where can media and investors contact Xenon (XENE) for more information ahead of the Q3 2025 call?
